Following on from our symposium More than Medication: Optimising Weight-Loss Drug Outcomes in Practice, we’ve pulled together some of the key resources and references discussed within the symposium. If you missed the live symposium, you can register to watch the recording.
BDA Obesity Specialist Group
NEW Patient resources:
Obesity Health Alliance:
If you’re interested in hearing more about the work of the OHA or want to find out more about their response to the obesity moonshot in the NHS 10 Year Plan, please email info@obesityhealthalliance.org.uk
All About Obesity
ASO
UK Congress on Obesity (UKCO) 2026. September 17, 2026
Session: Obesity management medications (OMMs) in the UK – what they mean in practice. Dr Alex Miras. Professor of Endocrinology
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038
Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022;28:2083–2091.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023;389:2221–2232.
Packer M, Butler J, Zannad F, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. New England Journal of Medicine. 2024.
Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine. 2023;389:514–526.
Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. Journal of Clinical Investigation. 2014;124(10):4473–4488.
van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WHM. Effects of the once-daily GLP-1 analogue liraglutide on gastric emptying, glycaemic parameters, appetite and energy metabolism in obese non-diabetic adults. International Journal of Obesity. 2014;38:784–793.
National Institute for Health and Care Excellence (NICE). Semaglutide for managing overweight and obesity. Technology appraisal guidance. Available at: https://www.nice.org.uk/guidance/ta875
NHS England. Interim commissioning guidance for weight management services and access to obesity pharmacotherapy. Available at: https://www.england.nhs.uk
Melson E, Miras AD, Papamargaritis D. Emerging gut hormone therapies for obesity management. International Journal of Obesity. 2024.
Session: Nutrition Strategies to support individuals taking weight loss medications. Nichola Ludlam-Raine. Registered Dietitian
Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine and the American Society for Nutrition. 2025.
Figure 1: Key elements of nutritional priorities to support GLP-1 therapy for obesity. Taken from Mozaffarian et al, 2025
Karakasis P, et al. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis. Metabolism. 2024;164:156113.
Neeland IJ, et al. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism. 2024;26(Suppl 4):16–27.
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384:989–1002.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205–216.
Hellström PM, Näslund E, Edholm T, et al. GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterology & Motility. 2008;20(6).
Lim MT, Pan BJ, Toh DWK, et al. Animal protein versus plant protein in supporting lean mass and muscle strength: a systematic review and meta-analysis of randomised controlled trials. Nutrients. 2021.
Further resources
How Not to Eat Ultra-Processed: Your 4-week plan for life-changing healthier eating habits. 2024. Nichola Ludlam-Raine.
Session: Safety, Monitoring and Accountability in GLP-1 Weight Loss Care. Louise Bula. Lead Dietitian, Teladoc Health International
National Institute for Health and Care Excellence (NICE). Semaglutide for managing overweight and obesity [TA875]. Available at: https://www.nice.org.uk/guidance/ta875
National Institute for Health and Care Excellence (NICE). Tirzepatide for managing overweight and obesity. Available at: https://www.nice.org.uk
Medicines and Healthcare products Regulatory Agency (MHRA). GLP-1 receptor agonists: monitoring, adverse effects and Yellow Card reporting guidance. Available at: https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
British Dietetic Association Obesity Specialist Group. Position statements and professional resources on obesity pharmacotherapy. Available at: https://www.bda.uk.com/resource/new-joint-statement-regarding-glp-1-gip-receptor-agonists-for-people-living-with-obesity-and-or-type-2-diabetes-released.html
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384:989–1002.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205–216.
Neeland IJ, et al. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism. 2024;26(Suppl 4):16–27.
BEAT Eating Disorders. Guidance on recognising eating disorders in weight-management settings. Available at: https://www.beateatingdisorders.org.uk
Royal College of Psychiatrists. Eating disorders and obesity: guidance for clinicians. Available at: https://www.rcpsych.ac.uk
Session: Beyond the Injection: Behaviour Change & Communication for Patients using GLP-1 Medication. Dr Nikita Rowley.
West S, Scragg J, Aveyard P, et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026;392:e085304. doi:10.1136/bmj-2025-085304
Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implementation Science. 2011;6:42.
Michie S, Atkins L, West R. The Behaviour Change Wheel: A Guide to Designing Interventions. Silverback Publishing; 2014.
Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: toward an integrative model of change. Journal of Consulting and Clinical Psychology. 1983;51(3):390–395.
Teixeira PJ, Carraça EV, Marques MM, et al. Successful behaviour change in obesity interventions in adults: a systematic review of self-regulation mediators. BMC Medicine. 2015;13:84.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205–216.
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384:989–1002.
Stubbs RJ, O’Reilly LM, Whybrow S, et al. Behavioural appetite control, satiety and food intake: understanding the role of GLP-1 receptor agonists in obesity care. Obesity Reviews. 2024.
British Psychological Society. Behaviour change: a guide for practitioners. Available at: https://www.bps.org.uk
National Institute for Health and Care Excellence (NICE). Behaviour change: individual approaches. NICE public health guideline [PH49]. Available at: https://www.nice.org.uk/guidance/ph49
Session: Long-Term Weight Maintenance after Obesity Medicines: Evidence and Practical Strategies. Angela Carvalho
Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022;24(8):1553–1564. doi:10.1111/dom.14725
Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38–48. doi:10.1001/jama.2023.24945
Lundgren JR, Janus C, Jensen SBK, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. New England Journal of Medicine. 2021;384:1719–1730. doi:10.1056/NEJMoa2028198
West S, Scragg J, Aveyard P, et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026;392:e085304. doi:10.1136/bmj-2025-085304
Budini B, Luo S, Tam M, et al. Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. 2026. doi:10.17863/CAM.126010
Wong M, Wu A, Garhe PK, Biermann M. Reduced-frequency GLP-1 therapy maintains weight, body composition, and metabolic syndrome improvements: a case series. Obesity. 2026. doi:10.1002/oby.70137
Rubino F, Puhl RM, Cummings DE, et al. Joint international consensus statement for ending stigma of obesity. Nature Medicine. 2020;26:485–497.
National Institute for Health and Care Excellence (NICE). Semaglutide for managing overweight and obesity [TA875]. Available at: https://www.nice.org.uk/guidance/ta875
Scottish Intercollegiate Guidelines Network (SIGN). Management of obesity. Available at: https://www.sign.ac.uk
British Dietetic Association Obesity Specialist Group. Resources on obesity management and GLP-1 therapies. Available at: https://www.bda.uk.com
Session: From biology to society: what weight-loss medications mean for the future of obesity care. Professor Giles Yeo.
National Child Measurement Programme. National Child Measurement Programme, England 2023/24 school year. Available at: https://digital.nhs.uk/data-and-information/publications/statistical/national-child-measurement-programme
Silventoinen K, Rokholm B, Kaprio J, Sørensen TIA. The genetic and environmental influences on childhood obesity: a systematic review of twin and adoption studies. International Journal of Obesity. 2010;34(1):29–40.
Locke AE, Kahali B, Berndt SI, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518:197–206.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384:989–1002.
Rubino F, Nathan DM, Eckel RH, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organisations. Diabetes Care. 2016;39(6):861–877.
Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism. 2018;27(4):740–756.
Yeo GSH, Heisler LK. Unraveling the brain regulation of appetite: lessons from genetics. Nature Neuroscience. 2012;15:1343–1349.
NICE. Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875]. Available at: https://www.nice.org.uk/guidance/ta875
Royal Society for Public Health. Health on the shelf: the impact of unhealthy food environments on obesity and health inequalities. Available at: https://www.rsph.org.uk
YOU MAY ALSO BE INTERESTED IN:
More than Medication: Optimising Weight-Loss Drug Outcomes in Practice
